THE BIOTECH GROWTH TRUST PLC
Interim Management Statement - 3 months to 30 June 2012 (unaudited)
The Biotech Growth Trust PLC seeks capital appreciation through investment in
the worldwide biotechnology industry principally by investing in emerging
biotechnology companies.
During the 3 month period ended 30 June 2012 the Company's net asset value per
share (NAV) rose by 11.0%, a strong performance compared to a 7.6% rise in the
Company's benchmark, the NASDAQ Biotechnology Index measured in sterling terms.
NAV performance was, in part, due to strong returns from portfolio holdings in
Questcor Pharmaceuticals, following reports of strong sales of its multiple
sclerosis treatment Acthar and also from Onyx Pharmaceuticals, following a
positive vote from a U.S. Food & Drug Administration Panel for the approval of
its drug Carfilzomib for the treatment of advanced Myeloma. The Company's
share price also performed well, increasing by 19.1% due, in part, to strong
demand from new retail shareholders; the share price ended the period on a 0.9%
premium to the Company's NAV. From the period-end to 18 July 2012, the
Company's NAV rose by 3.2% and the share price fell by 0.2%; this compares to a
rise of 3.9% in the Company's benchmark.
During the three-month period ended 30 June 2012, 19,079 shares were
repurchased for cancellation at a cost of £47,000 including expenses. The
Company also issued 275,000 new shares, at a premium to the prevailing NAV,
raising £681,000 of new funds for the Company. From 30 June 2012 to 18 July
2012, no new shares have been issued nor shares repurchased for cancellation.
At the Company's Annual General Meeting, held on 12 July 2012, all of the
resolutions were passed. The Chairman, Mr John Sclater, CVO, retired from the
Board at the conclusion of the Annual General Meeting and he was succeeded in
this role by Lord Waldegrave of North Hill.
Trust Characteristics
30 June 2012 31 March 2012
Number of Holdings 44 41
Net Assets (£m) 174.1 156.1
Gearing (AIC basis) 104 100
Share Price (p) 281.13 236.0
NAV (p) 278.57 250.86
Premium/(Discount) 0.9% (5.9%)
Source: Frostrow Capital LLP
Geographical Analysis
% of portfolio % of portfolio
at 30 June 2012 at 31 March 2012
North America 87.6 86.8
Continental Europe 8.6 9.5
Far East 2.8 2.5
Unquoted 1.0 1.2
Total 100.0 100.0
Source: Frostrow Capital LLP
10 Largest Investments
Name
% of portfolio % of portfolio
at 30 June 2012 at 31 March 2012
Gilead Sciences 7.1 8.6
Amgen 6.4 6.7
Questcor Pharmaceutical 5.0 5.6
Perrigo 4.7 4.7
Celgene 4.5 6.1
Onyx Pharmaceuticals 4.3 2.6
Auxilium Pharmaceuticals 4.2 -
Alexion Pharmaceuticals 4.1 4.3
Incyte Genomics 4.0 4.2
Biogen Idec 3.9 3.9
Total 48.2 46.7
Source: Frostrow Capital LLP
Performance to 30 June 2012
3 Months 1 Year 3 Years 5 Years
Share Price +19.1 +47.0 +132.3 +160.3
NAV per share +11.0 +35.4 +110.3 +142.4
Benchmark* +7.6 +24.9 +89.3 +115.5
Source: Bloomberg & Morningstar
* Benchmark - NASDAQ Biotechnology Index measured in sterling terms.
Past performance is not a guide to future performance.
This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.
This Interim Management Statement is available on the Company's website
www.biotechgt.com.
The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com
SEDOL Code: - Ordinary shares - 0038551
ISIN: - Ordinary Shares GB0000385517
Bloomberg: - BIOG LN
EPIC: - BIOG
For further information contact: Mark Pope on 0203 008 4913
Frostrow Capital LLP
Company Secretary
20 July 2012
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.